Tazverik — CareFirst (Caremark)
metastatic or locally advanced epithelioid sarcoma not eligible for complete resection
Initial criteria
- metastatic or locally advanced epithelioid sarcoma
- used as a single agent
- member age ≥ 16 years
- disease not eligible for complete resection
Reauthorization criteria
- no evidence of unacceptable toxicity
- no evidence of disease progression while on the current regimen
Approval duration
12 months